Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABOSTO:QLINEA -1.19%65 EV-to-FCF is -0.98 as of Jul. 21, 2026. GuruFocus rates OSTO:QLINEA with a GF Score™ of 65/100 and a GF Value™ of kr19.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Q-linea AB ranks worse than 241545.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Q-linea AB's Enterprise Value is kr139.45 Mil.
Q-linea AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr-142.51 Mil. Therefore, Q-linea AB's EV-to-FCF for today is -0.98.
The historical rank and industry rank for Q-linea AB's EV-to-FCF or its related term are showing as below:
OSTO:QLINEA'
s EV-to-FCF Range Over the Past 10 Years
Min: -2029.09 Med: -6.44 Max: -0.16
Current: -1.01
During the past 11 years, the highest EV-to-FCF of Q-linea AB was -0.16. The lowest was -2029.09. And the median was -6.44.
OSTO:QLINEA's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.21
vs OSTO:QLINEA: -1.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Q-linea AB's share price for today is kr16.60.
Q-linea AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-13.196.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Q-linea AB EV-to-FCF Related Terms
Q-linea AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Q-linea AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLINEA vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Q-linea AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Q-linea AB's EV-to-FCF falls into.
Q-linea AB's current Enterprise Value is kr139.45 Mil.
Q-linea AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-142.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (OSTO:QLINEA) has a EV-to-FCF of -0.98 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Q-linea AB's EV-to-FCF too high?
Q-linea AB's current EV-to-FCF is -0.98. Based on the distribution chart, Q-linea AB ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #999999 out of 414 companies for EV-to-FCF. This places Q-linea AB in the lower half of its industry. The industry median EV-to-FCF is 23.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.21, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current EV-to-FCF is -0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Based on GuruFocus' analysis, Q-linea AB (OSTO:QLINEA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr19.61, compared to a current price of kr16.60 — trading 15.3% below its estimated fair value. The current EV-to-FCF is -0.98. Q-linea AB's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Q-linea AB (OSTO:QLINEA), the current EV-to-FCF is -0.98 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (OSTO:QLINEA) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr16.60 is trading 15.3% below its estimated GF Value™ of kr19.61.
GuruFocus considers Q-linea AB to be Modestly Undervalued.
Key valuation signals for OSTO:QLINEA:
EV-to-FCF: -0.98
GF Value™: kr19.61 vs. price of kr16.60 (15.3% below fair value)
No single metric tells the full story. See the OSTO:QLINEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
65GF Score
Get the complete analysis for OSTO:QLINEA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLINEA has been successfully added to your 
